Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction.

Goldfischer ER, Kim ED, Seftel AD, Baygani SK, Burns PR.

Urology. 2014 Jun;83(6):1326-33. doi: 10.1016/j.urology.2014.02.019. Epub 2014 Apr 13.

PMID:
24726311
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study.

Goldfischer ER, Sand PK, Thomas H, Peters-Gee J.

Neurourol Urodyn. 2013 Oct 16. doi: 10.1002/nau.22504. [Epub ahead of print]

PMID:
24133005
[PubMed - as supplied by publisher]
3.

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.

Urology. 2013 Sep;82(3):667-73. doi: 10.1016/j.urology.2013.05.005. Epub 2013 Jul 19. Erratum in: Urology. 2014 Mar;83(3):684.

PMID:
23876588
[PubMed - indexed for MEDLINE]
4.

A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.

Kim ED, Seftel AD, Goldfischer ER, Ni X, Burns PR.

J Sex Med. 2014 Mar;11(3):820-30. doi: 10.1111/jsm.12253. Epub 2013 Jul 10.

PMID:
23841532
[PubMed - in process]
5.

Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.

Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group.

Menopause. 2013 Jun;20(6):623-30. doi: 10.1097/gme.0b013e318279ba64.

PMID:
23361170
[PubMed - indexed for MEDLINE]
6.

Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder.

Clayton AH, Goldfischer E, Goldstein I, DeRogatis L, Nappi R, Lewis-D'Agostino DJ, Kimura T, Hebert A, Pyke R.

J Sex Marital Ther. 2013;39(2):132-43. doi: 10.1080/0092623X.2011.606496.

PMID:
23252638
[PubMed - indexed for MEDLINE]
7.

Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.

Goldfischer E, Kowalczyk JJ, Clark WR, Brady E, Shane MA, Dgetluck N, Klise SR.

Urology. 2012 Apr;79(4):875-82. doi: 10.1016/j.urology.2011.11.040. Epub 2012 Feb 14.

PMID:
22341603
[PubMed - indexed for MEDLINE]
8.

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.

Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Kimura T, Sand M, Pyke R.

J Sex Med. 2011 Nov;8(11):3160-72. doi: 10.1111/j.1743-6109.2011.02458.x. Epub 2011 Sep 20.

PMID:
21933348
[PubMed - indexed for MEDLINE]
9.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.

Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L.

BJU Int. 2011 Apr;107(7):1110-6. doi: 10.1111/j.1464-410X.2010.09687.x. Epub 2011 Jan 18.

PMID:
21244606
[PubMed - indexed for MEDLINE]
10.

Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial.

Seftel A, Goldfischer E, Kim ED, Dula E, Zeigler H, Burns P.

J Urol. 2011 Jan;185(1):243-8. doi: 10.1016/j.juro.2010.09.035. Epub 2010 Nov 13.

PMID:
21074803
[PubMed - indexed for MEDLINE]
11.

Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.

Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Choo MS.

BJU Int. 2011 Feb;107(4):603-11. doi: 10.1111/j.1464-410X.2010.09587.x. Epub 2010 Sep 22.

PMID:
20860648
[PubMed - indexed for MEDLINE]
12.

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL; Bladder Cancer Genitourinary Oncology Study Group.

J Urol. 2010 Nov;184(5):1915-9. doi: 10.1016/j.juro.2010.06.147. Epub 2010 Sep 17.

PMID:
20846688
[PubMed - indexed for MEDLINE]
13.

Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrate.

Ströberg P, Kaminetsky JC, Park NC, Goldfischer ER, Creanga DL, Stecher VJ.

Int J Impot Res. 2010 Jul-Aug;22(4):284-9. doi: 10.1038/ijir.2010.17. Epub 2010 Jul 1.

PMID:
20596083
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent.

Krambeck AE, Walsh RS, Denstedt JD, Preminger GM, Li J, Evans JC, Lingeman JE; Lexington Trial Study Group.

J Urol. 2010 Mar;183(3):1037-42. doi: 10.1016/j.juro.2009.11.035. Epub 2010 Jan 21.

PMID:
20092835
[PubMed - indexed for MEDLINE]
15.

Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.

Kaplan SA, Goldfischer ER, Steers WD, Gittelman M, Andoh M, Forero-Schwanhaeuser S.

Aging Male. 2010 Jun;13(2):100-7. doi: 10.3109/13685530903440408.

PMID:
20001469
[PubMed - indexed for MEDLINE]
16.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.

N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.

PMID:
19671656
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Assessing the impact of ureteral stent design on patient comfort.

Lingeman JE, Preminger GM, Goldfischer ER, Krambeck AE; Comfort Study Team.

J Urol. 2009 Jun;181(6):2581-7. doi: 10.1016/j.juro.2009.02.019. Epub 2009 Apr 16.

PMID:
19375088
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.

Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z, Choo MS.

Int J Clin Pract. 2009 Apr;63(4):560-7.

PMID:
19348029
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD).

Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D'Agostino DJ, Pyke R.

J Sex Med. 2009 Mar;6(3):730-8. doi: 10.1111/j.1743-6109.2008.01153.x. Epub 2009 Jan 13.

PMID:
19170868
[PubMed - indexed for MEDLINE]
20.

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group.

J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17.

PMID:
18801505
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk